As of Friday close, Gossamer Bio Inc.’s (NASDAQ:GOSS) stock was down -$0.03, moving down -3.96 percent to $0.80. The average number of shares traded per day over the past five days has been 2,464,100 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.1207 fall in that time frame. In the last twenty days, the average volume was 2,549,275, while in the previous 50 days, it was 2,467,274.
Since last month, GOSS stock retreated -23.84%. Shares of the company fell to $0.7831 on 09/22/23, the lowest level in the past month. A 52-week high of $13.68 was reached on 02/02/23 after having rallying from a 52-week low of $0.82. Since the beginning of this year, GOSS’s stock price has dropped by -63.15% or -$1.3703, and marked a new high 9 times. However, the stock has declined by -94.15% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
GOSS stock investors should be aware that Gossamer Bio Inc. (GOSS) stock had its last reported insider trading activity 93 days ago on Jun 22. Aranda Richard, the Chief Medical Officer of the company, disposed of 1,814 shares for $1.29 on Jun 22. It resulted in a $2,340 divestment by the insider. Giraudo Bryan added 55,000 shares at an average price of $1.02 on Apr 04. The insider now owns 125,990 shares following the transaction. On Mar 22, President & CEO Hasnain Faheem bought 440,500 shares at $1.14 apiece. The transaction was valued at $503,580.
Financial Health
In the three months ended June 29, Gossamer Bio Inc.’s quick ratio stood at 4.30, while its current ratio was 4.30, showing that the company is able to pay off its debt. Based on annual data, GOSS earned $13.88 million in gross profit and brought in $218.59 million in revenue.
In Gossamer Bio Inc.’s quarter-end financial report for June 29, it reported total debt of $6.44 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Gossamer Bio Inc. to report -$0.49 quarterly earnings, the actual figure was -$0.45 per share, beating the consensus estimate by 8.20%. During the quarter, the company generated -$46.32 million in EBITDA. The liabilities of Gossamer Bio Inc. were 244.55 million at the end of its most recent quarter ended June 29, and its total debt was $219.16 million. The value of shareholders’ equity is $225.32 million.
Technical Picture
This quick technical analysis looks at Gossamer Bio Inc.’s (GOSS) price momentum. With a historical volatility rate of 54.13%, the RSI 9-day stood at 22.79% on 22 September.
With respect to its five-day moving average, the current Gossamer Bio Inc. price is down by -13.11% percent or -$0.1207. At present, GOSS shares trade -22.36% below its 20-day simple moving average and -39.42% percent below its 100-day simple moving average. However, the stock is currently trading approximately -48.24% below its SMA50 and -91.39% below its SMA200.
Stochastic coefficient K was 8.00% and Stochastic coefficient D was 17.22%, while ATR was 0.0748. Given the Stochastic reading of 5.41% for the 14-day period, the RSI (14) reading has been calculated as 28.06%. As of today, the MACD Oscillator reading stands at -0.0563, while the 14-day reading stands at -0.0914.
Analyst Ratings
Gossamer Bio Inc. downgraded its rating on Gossamer Bio Inc. (NASDAQ: GOSS) to a Neutral in a note to investors on July 27, 2023. The analysts firm previously had a Buy rating on the stock.Gossamer Bio Inc. (GOSS) has been rated Overweight by analysts. According to 1 brokerage firm, GOSS is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Gossamer Bio Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $4.00, the current consensus forecast for the stock is $1.25 – $15.00. Based on these forecasts, analysts predict Gossamer Bio Inc. (GOSS) will achieve an average price target of $5.31.
